Patient Materials

Here are some helpful materials for your own use. Just click on the link and print out any or all of these resources. You can also read an excerpt from A Guide to Living With von Willebrand Disease.

Medications to Avoid
Here you’ll find a listing of medications to avoid if you have VWD.

Activities to Enjoy
This page has information on recommended physical activities if you have VWD.

My Journal
If you are a woman with VWD, use this journal to keep track of your periods and related information. It can also be a helpful tool for your next visit with your doctor.

A Guide to Living With von Willebrand Disease: Complete a quick registration page and we will send you this guide—the first book-length resource about VWD. A Guide to Living With von Willebrand Disease was written by Renée Paper, RN, a healthcare professional with VWD, and Laureen A. Kelley, author and mother of a child with hemophilia.

Renée was a tireless advocate for people with bleeding disorders, especially VWD. She passed away in November 2007, but her contributions to the bleeding disorders community will live on. Laureen is the author of numerous books on bleeding disorders and the president of LA Kelley Communications, Inc., a provider of educational resources and leadership training for the bleeding disorders community.

A Guide to Living With von Willebrand Disease provides valuable information on living with the disease. Read an excerpt right now and view the front and back covers, foreword, and preface by clicking the images below.

Front Cover

Foreword

Preface

Excerpt

Back Cover

Important Safety Information

Humate-P is indicated for treatment and prevention of bleeding in adult patients with hemophilia A (classical hemophilia). Humate-P is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate. Humate-P is not indicated for the prophylaxis of spontaneous bleeding episodes.

Humate-P is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations.

Monitor for intravascular hemolysis and decreasing hematocrit values in patients with A, B, and AB blood groups who are receiving large or frequent doses. Also monitor VWF:RCo and FVIII levels in VWD patients, especially those undergoing surgery.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement. Caution should be exercised and antithrombotic measures considered, particularly in patients with known risk factors for thrombosis.

Humate-P is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

In patients receiving Humate-P in clinical studies for treatment of VWD, the most commonly reported adverse reactions observed by >5% of subjects are allergic-anaphylactic reactions, including urticaria (hives), chest tightness, rash, pruritus (itching), and edema (swelling). For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding, and epistaxis (nosebleed).

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.